Intersect ENT focuses on developing innovative medical technologies aimed at improving patient care for those suffering from chronic rhinosinusitis. Their product line includes a range of less invasive and cost-effective solutions designed to enhance treatment outcomes. Key offerings include the PROPEL family of implants, which are designed to deliver corticosteroids directly to the sinus tissue, thereby reducing inflammation and promoting healing. The PROPEL Mini and PROPEL Contour are variations that cater to different patient needs, while SINUVA is another product that provides a non-surgical option for managing nasal polyps.

The company emphasizes the integration of these technologies into clinical practice, ensuring that they are not only effective but also accessible to patients. Intersect ENT's commitment to innovation is reflected in their ongoing research and development efforts, which aim to expand their product pipeline and improve existing solutions. Their technologies are protected by a robust portfolio of patents, underscoring the uniqueness and proprietary nature of their offerings in the field of ENT care.

United States

XENT was acquired by MDT on 5/13/2022

Intersect ENT (Nasdaq:XENT) is a medical technology company dedicated to advancing the treatment of ear, nose and throat (ENT) conditions through evidence-based innovation, providing physicians with solutions to overcome clinical challenges and improve the quality of life for patients.


Intersect ENT

Company Details